{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T06:45:57Z","timestamp":1742971557381,"version":"3.40.3"},"publisher-location":"Berlin, Heidelberg","reference-count":37,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642294228"},{"type":"electronic","value":"9783642294235"}],"license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.1007\/978-3-642-29423-5_23","type":"book-chapter","created":{"date-parts":[[2012,8,23]],"date-time":"2012-08-23T05:26:30Z","timestamp":1345699590000},"page":"565-605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Primary Prevention of Ischaemic Cardiovascular Disorders with Antiplatelet Agents"],"prefix":"10.1007","author":[{"given":"Tom","family":"Meade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,23]]},"reference":[{"unstructured":"A Study of Cardiovascular Events in Diabetes (ASCEND) Study (2008) http:\/\/www.ctsu.ox.ac.uk\/ascend\/. Accessed 23 April 2009","key":"23_CR1"},{"issue":"7329","key":"23_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71\u201386","journal-title":"BMJ"},{"unstructured":"Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) Study (2008) http:\/\/www.arrive-study.com\/EN\/study.cfm. Accessed 23 April 2009","key":"23_CR3"},{"issue":"9678","key":"23_CR4","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849\u20131860","journal-title":"Lancet"},{"key":"23_CR5","doi-asserted-by":"publisher","first-page":"a1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"J Belch","year":"2008","unstructured":"Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R et al (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337:a1840","journal-title":"BMJ"},{"issue":"16","key":"23_CR6","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE et al (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354(16):1706\u20131717","journal-title":"N Engl J Med"},{"issue":"9809","key":"23_CR7","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","volume":"378","author":"J Burn","year":"2011","unstructured":"Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378(9809):2081\u20132087","journal-title":"Lancet"},{"key":"23_CR8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329\u20131339","journal-title":"Lancet"},{"issue":"9497","key":"23_CR9","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","volume":"366","author":"ZM Chen","year":"2005","unstructured":"Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497):1607\u20131621","journal-title":"Lancet"},{"issue":"9250","key":"23_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","volume":"357","author":"Collaborative Group of the Primary Prevention Project (PPP)","year":"2001","unstructured":"Collaborative Group of the Primary Prevention Project (PPP) (2001) Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 357(9250):89\u201395","journal-title":"Lancet"},{"key":"23_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1745-6215-8-21","volume":"8","author":"BG De","year":"2007","unstructured":"De BG, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G et al (2007) Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 8:21","journal-title":"Trials"},{"key":"23_CR12","first-page":"413","volume":"29","author":"PC Elwood","year":"1979","unstructured":"Elwood PC, Williams WO (1979) A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction. J Royl Coll GPs 29:413\u2013416","journal-title":"J Royl Coll GPs"},{"issue":"905","key":"23_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/bmj.1.5905.436","volume":"1","author":"PC Elwood","year":"1974","unstructured":"Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E et al (1974) A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1(905):436\u2013440","journal-title":"BMJ"},{"issue":"9671","key":"23_CR14","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(09)60243-9","volume":"373","author":"PC Elwood","year":"2009","unstructured":"Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G (2009) Aspirin, salicylates, and cancer. Lancet 373(9671):1301\u20131309","journal-title":"Lancet"},{"issue":"10","key":"23_CR15","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1001\/jama.1992.03490100090033","volume":"268","author":"ETDRS Investigators","year":"1992","unstructured":"ETDRS Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. JAMA 268(10):1292\u20131300","journal-title":"JAMA"},{"issue":"12","key":"23_CR16","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","volume":"54","author":"B Farrell","year":"1991","unstructured":"Farrell B, Godwin J, Richards S, Warlow C (1991) The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54(12):1044\u20131054","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9573","key":"23_CR17","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(07)60747-8","volume":"369","author":"E Flossmann","year":"2007","unstructured":"Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369(9573):1603\u20131613","journal-title":"Lancet"},{"key":"23_CR18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/ije\/20.2.384","volume":"20","author":"FGR Fowkes","year":"1991","unstructured":"Fowkes FGR, Housley E, Cawood EHH, MacIntyre CCA, Ruckley CV, Prescott RJ (1991) Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 20:384\u2013392","journal-title":"Int J Epidemiol"},{"issue":"9","key":"23_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jama.2010.221","volume":"303","author":"FG Fowkes","year":"2010","unstructured":"Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC et al (2010) Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303(9):841\u2013848","journal-title":"JAMA"},{"issue":"9118","key":"23_CR20","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351(9118):1755\u20131762","journal-title":"Lancet"},{"key":"23_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/bmj.321.7252.13","volume":"321","author":"TW Meade","year":"2000","unstructured":"Meade TW, Brennan PJ (2000) Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 321:13\u201317","journal-title":"BMJ"},{"key":"23_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(86)90111-X","volume":"2","author":"TW Meade","year":"1986","unstructured":"Meade TW, Brozovic M, Chakrabarti RR, Haines AP, Imeson JD, Mellows S et al (1986) Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2:533\u2013537","journal-title":"Lancet"},{"key":"23_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","volume":"351","author":"Medical Research Council's General Practice Research Framework","year":"1998","unstructured":"Medical Research Council's General Practice Research Framework (1998) Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351:233\u2013241","journal-title":"Lancet"},{"issue":"12","key":"23_CR24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2165\/00002512-200320120-00004","volume":"20","author":"M Nelson","year":"2003","unstructured":"Nelson M, Reid C, Beilin L, Donnan G, Johnston C, Krum H et al (2003) Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging 20(12):897\u2013903","journal-title":"Drugs Aging"},{"issue":"18","key":"23_CR25","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1001\/jama.2008.623","volume":"300","author":"H Ogawa","year":"2008","unstructured":"Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N et al (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300(18):2134\u20132141","journal-title":"JAMA"},{"key":"23_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","volume":"296","author":"R Peto","year":"1988","unstructured":"Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K et al (1988) Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 296:313\u2013316","journal-title":"BMJ"},{"issue":"13","key":"23_CR27","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa050613","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE et al (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352(13):1293\u20131304","journal-title":"N Engl J Med"},{"issue":"9754","key":"23_CR28","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","volume":"376","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376(9754):1741\u20131750","journal-title":"Lancet"},{"issue":"9759","key":"23_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","volume":"377","author":"PM Rothwell","year":"2011","unstructured":"Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759):31\u201341","journal-title":"Lancet"},{"issue":"9826","key":"23_CR33","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","volume":"379","author":"PM Rothwell","year":"2012","unstructured":"Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379(9826):1591\u20131601","journal-title":"Lancet"},{"issue":"12","key":"23_CR30","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352(12):1179\u20131189","journal-title":"N Engl J Med"},{"issue":"19","key":"23_CR31","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"SR Steinhubl","year":"2002","unstructured":"Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19):2411\u20132420","journal-title":"JAMA"},{"key":"23_CR32","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"The Clopidogrel in Unstable Angina to Prevent Recurrent Events Investigators","year":"2001","unstructured":"The Clopidogrel in Unstable Angina to Prevent Recurrent Events Investigators (2001) Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes Without ST-Segment Elevation. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Investigators. N Engl J Med 345:494\u2013502","journal-title":"N Engl J Med"},{"key":"23_CR34","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/0140-6736(91)92233-R","volume":"338","author":"The SALT Collaborative Group","year":"1991","unstructured":"The SALT Collaborative Group (1991) Swedish Aspirin Low-dose Trial (SALT) of 75\u00a0mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338:1345\u20131349","journal-title":"Lancet"},{"key":"23_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJM198907203210301","volume":"321","author":"The Steering Committee of the Physicians\u2019 Health Study Research Group","year":"1989","unstructured":"The Steering Committee of the Physicians\u2019 Health Study Research Group (1989) Final report on the aspirin component of the ongoing physicians\u2019 health study. N Eng J Med 321:129\u2013135","journal-title":"N Eng J Med"},{"key":"23_CR36","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7326\/0003-4819-150-6-200903170-00008","volume":"150","author":"U.S. Preventive Services Task Force","year":"2009","unstructured":"U.S. Preventive Services Task Force (2009) Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 150:396\u2013405, Ref type: Generic","journal-title":"Ann Intern Med"},{"key":"23_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0140-6736(67)91658-3","volume":"2","author":"HJ Weiss","year":"1967","unstructured":"Weiss HJ, Aledort LM (1967) Impaired platelet\/connective-tissue reaction in man after aspirin ingestion. Lancet 2:495\u2013497","journal-title":"Lancet"}],"container-title":["Handbook of Experimental Pharmacology","Antiplatelet Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-29423-5_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T00:38:23Z","timestamp":1676162303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-29423-5_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"ISBN":["9783642294228","9783642294235"],"references-count":37,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-29423-5_23","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"type":"print","value":"0171-2004"},{"type":"electronic","value":"1865-0325"}],"subject":[],"published":{"date-parts":[[2012]]},"assertion":[{"value":"23 July 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}